Heart Failure With Targeted Cancer Therapies

DOI Web Site 1 Citations
  • Virginia S. Hahn
    Division of Cardiology, Johns Hopkins School of Medicine, Baltimore, MD (V.S.H.).
  • Kathleen W. Zhang
    Cardio-Oncology Center of Excellence, Washington University, St Louis, MO (K.W.Z., D.J.L.).
  • Lova Sun
    Penn Cardio-Oncology Translational Center of Excellence, Abramson Cancer Center (L.S., V.N., B.K.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  • Vivek Narayan
    Penn Cardio-Oncology Translational Center of Excellence, Abramson Cancer Center (L.S., V.N., B.K.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  • Daniel J. Lenihan
    Cardio-Oncology Center of Excellence, Washington University, St Louis, MO (K.W.Z., D.J.L.).
  • Bonnie Ky
    Penn Cardio-Oncology Translational Center of Excellence, Abramson Cancer Center (L.S., V.N., B.K.), Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Bibliographic Information

Other Title
  • Mechanisms and Cardioprotection

Abstract

<jats:p>Oncology has seen growing use of newly developed targeted therapies. Although this has resulted in dramatic improvements in progression-free and overall survival, challenges in the management of toxicities related to longer-term treatment of these therapies have also become evident. Although a targeted approach often exploits the differences between cancer cells and noncancer cells, overlap in signaling pathways necessary for the maintenance of function and survival in multiple cell types has resulted in systemic toxicities. In particular, cardiovascular toxicities are of important concern. In this review, we highlight several targeted therapies commonly used across a variety of cancer types, including HER2 (human epidermal growth factor receptor 2)+ targeted therapies, tyrosine kinase inhibitors, immune checkpoint inhibitors, proteasome inhibitors, androgen deprivation therapies, and MEK (mitogen-activated protein kinase kinase)/BRAF (v-raf murine sarcoma viral oncogene homolog B) inhibitors. We present the oncological indications, heart failure incidence, hypothesized mechanisms of cardiotoxicity, and potential mechanistic rationale for specific cardioprotective strategies.</jats:p>

Journal

  • Circulation Research

    Circulation Research 128 (10), 1576-1593, 2021-05-14

    Ovid Technologies (Wolters Kluwer Health)

Citations (1)*help

See more

Details 詳細情報について

Report a problem

Back to top